HUTCHMED (China) Limited (0013.HK)
HKD 23.0
(-0.22%)
HKD 23.0
(-0.22%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | - USD | 114.41% |
| 2022 | -409.77 Million USD | -21.79% |
| 2021 | -336.45 Million USD | -78.07% |
| 2020 | -188.94 Million USD | -30.29% |
| 2019 | -145.01 Million USD | -56.54% |
| 2018 | -92.64 Million USD | -73.43% |
| 2017 | -53.41 Million USD | -14.39% |
| 2016 | -46.69 Million USD | -377.91% |
| 2015 | -9.77 Million USD | -220.63% |
| 2014 | 8.1 Million USD | -29.9% |
| 2013 | 11.55 Million USD | -4.59% |
| 2012 | 12.11 Million USD | 124.77% |
| 2011 | 5.38 Million USD | 344.06% |
| 2010 | -2.2 Million USD | 52.16% |
| 2009 | -4.61 Million USD | 67.57% |
| 2008 | -14.22 Million USD | -46.33% |
| 2007 | -9.72 Million USD | -80.62% |
| 2006 | -5.38 Million USD | 6.03% |
| 2005 | -5.72 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -13.76 Million USD | 70.5% |
| 2024 Q2 | -13.76 Million USD | 0.0% |
| 2023 Q1 | 55.82 Million USD | 152.93% |
| 2023 FY | 59.06 Million USD | 114.41% |
| 2023 Q4 | -46.63 Million USD | 0.0% |
| 2023 Q3 | -46.63 Million USD | -183.54% |
| 2023 Q2 | 55.82 Million USD | 0.0% |
| 2022 Q2 | -98.37 Million USD | 0.0% |
| 2022 Q3 | -105.46 Million USD | -7.21% |
| 2022 FY | -409.77 Million USD | -21.79% |
| 2022 Q4 | -105.46 Million USD | 0.0% |
| 2022 Q1 | -98.37 Million USD | -6.59% |
| 2021 Q4 | -92.29 Million USD | 0.0% |
| 2021 Q3 | -92.29 Million USD | -14.6% |
| 2021 FY | -336.45 Million USD | -78.07% |
| 2021 Q2 | -80.53 Million USD | -27.43% |
| 2021 Q1 | -63.2 Million USD | -6.66% |
| 2020 Q3 | -59.25 Million USD | -29.73% |
| 2020 FY | -188.94 Million USD | -30.29% |
| 2020 Q1 | -32.49 Million USD | 15.46% |
| 2020 Q2 | -45.67 Million USD | -40.57% |
| 2020 Q4 | -59.25 Million USD | 0.0% |
| 2019 Q2 | -35.96 Million USD | 0.25% |
| 2019 Q1 | -36.05 Million USD | -49.15% |
| 2019 FY | -145.01 Million USD | -56.54% |
| 2019 Q4 | -38.43 Million USD | -6.94% |
| 2019 Q3 | -35.94 Million USD | 0.06% |
| 2018 Q3 | -14.78 Million USD | 48.41% |
| 2018 FY | -92.64 Million USD | -73.43% |
| 2018 Q2 | -28.66 Million USD | -14.55% |
| 2018 Q1 | -25.02 Million USD | -33.97% |
| 2018 Q4 | -24.17 Million USD | -63.44% |
| 2017 FY | -53.41 Million USD | -14.39% |
| 2017 Q4 | -18.67 Million USD | 0.0% |
| 2017 Q1 | -8.03 Million USD | 47.74% |
| 2017 Q3 | -18.67 Million USD | -132.51% |
| 2017 Q2 | -8.03 Million USD | 0.0% |
| 2016 FY | -46.69 Million USD | -377.91% |
| 2016 Q4 | -15.37 Million USD | 0.0% |
| 2016 Q3 | -15.37 Million USD | -92.64% |
| 2016 Q2 | -7.97 Million USD | 0.0% |
| 2016 Q1 | -7.97 Million USD | -8679.03% |
| 2015 Q1 | -16 Thousand USD | -100.08% |
| 2015 FY | -9.77 Million USD | -220.63% |
| 2015 Q4 | 93 Thousand USD | 100.64% |
| 2015 Q3 | -14.47 Million USD | -90337.5% |
| 2015 Q2 | -16 Thousand USD | 0.0% |
| 2014 Q2 | -2.17 Million USD | 0.0% |
| 2014 Q1 | -2.17 Million USD | 78.73% |
| 2014 Q4 | 20.2 Million USD | 200.16% |
| 2014 FY | 8.1 Million USD | -29.9% |
| 2014 Q3 | -20.17 Million USD | -829.54% |
| 2013 Q1 | -2.46 Million USD | 45.62% |
| 2013 Q2 | -2.46 Million USD | 0.0% |
| 2013 Q3 | 1.94 Million USD | 178.74% |
| 2013 Q4 | -10.2 Million USD | -624.63% |
| 2013 FY | 11.55 Million USD | -4.59% |
| 2012 FY | 12.11 Million USD | 124.77% |
| 2012 Q4 | -4.54 Million USD | 0.0% |
| 2012 Q3 | -4.54 Million USD | 0.0% |
| 2011 FY | 5.38 Million USD | 344.06% |
| 2010 FY | -2.2 Million USD | 52.16% |
| 2009 FY | -4.61 Million USD | 67.57% |
| 2008 FY | -14.22 Million USD | -46.33% |
| 2007 FY | -9.72 Million USD | -80.62% |
| 2006 FY | -5.38 Million USD | 6.03% |
| 2005 FY | -5.72 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 100.0% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 100.0% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 100.0% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | 100.0% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 100.0% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | 100.0% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 100.0% |
| Tongfang Kontafarma Holdings Limited | - HKD | NaN% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 100.0% |
| SSY Group Limited | 1.63 Billion HKD | 100.0% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 100.0% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 100.0% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 100.0% |